
Paul V. Ward
Examiner (ID: 4583)
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1622, 1623 |
| Total Applications | 2519 |
| Issued Applications | 1801 |
| Pending Applications | 239 |
| Abandoned Applications | 539 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15225011
[patent_doc_number] => 10500209
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-10
[patent_title] => Quinazolinones as bromodomain inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/821454
[patent_app_country] => US
[patent_app_date] => 2017-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39891
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821454
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/821454 | Quinazolinones as bromodomain inhibitors | Nov 21, 2017 | Issued |
Array
(
[id] => 14775123
[patent_doc_number] => 20190262459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/343979
[patent_app_country] => US
[patent_app_date] => 2017-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343979
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/343979 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | Nov 21, 2017 | Issued |
Array
(
[id] => 14775121
[patent_doc_number] => 20190262458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/343974
[patent_app_country] => US
[patent_app_date] => 2017-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343974
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/343974 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | Nov 21, 2017 | Issued |
Array
(
[id] => 14945713
[patent_doc_number] => 10434102
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-08
[patent_title] => Organic light emitting device
[patent_app_type] => utility
[patent_app_number] => 15/819884
[patent_app_country] => US
[patent_app_date] => 2017-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 9384
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819884
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/819884 | Organic light emitting device | Nov 20, 2017 | Issued |
Array
(
[id] => 12580908
[patent_doc_number] => 20180085465
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-29
[patent_title] => METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
[patent_app_type] => utility
[patent_app_number] => 15/816646
[patent_app_country] => US
[patent_app_date] => 2017-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 238
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15816646
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/816646 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | Nov 16, 2017 | Abandoned |
Array
(
[id] => 16429397
[patent_doc_number] => 10829464
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-10
[patent_title] => Benzoheterocyclic alkylamine compounds and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/461234
[patent_app_country] => US
[patent_app_date] => 2017-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 18657
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 187
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461234
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/461234 | Benzoheterocyclic alkylamine compounds and use thereof | Nov 16, 2017 | Issued |
Array
(
[id] => 12728521
[patent_doc_number] => 20180134674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-17
[patent_title] => MAGL INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 15/814322
[patent_app_country] => US
[patent_app_date] => 2017-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42541
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 266
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15814322
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/814322 | MAGL inhibitors | Nov 14, 2017 | Issued |
Array
(
[id] => 13026325
[patent_doc_number] => 10035778
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-31
[patent_title] => Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
[patent_app_type] => utility
[patent_app_number] => 15/812986
[patent_app_country] => US
[patent_app_date] => 2017-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 28563
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15812986
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/812986 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | Nov 13, 2017 | Issued |
Array
(
[id] => 14836103
[patent_doc_number] => 20190276452
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS
[patent_app_type] => utility
[patent_app_number] => 16/349580
[patent_app_country] => US
[patent_app_date] => 2017-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 236
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349580
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/349580 | Selective inhibitors of gentotoxic steress-induced IKK/NF-kB pathways | Nov 13, 2017 | Issued |
Array
(
[id] => 13440647
[patent_doc_number] => 20180271866
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-27
[patent_title] => 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 15/809107
[patent_app_country] => US
[patent_app_date] => 2017-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809107
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/809107 | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | Nov 9, 2017 | Issued |
Array
(
[id] => 16861674
[patent_doc_number] => 11020396
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-01
[patent_title] => Pyrimidinone derivatives as Cdc7 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/348073
[patent_app_country] => US
[patent_app_date] => 2017-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36452
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 559
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/348073 | Pyrimidinone derivatives as Cdc7 inhibitors | Nov 6, 2017 | Issued |
Array
(
[id] => 14913603
[patent_doc_number] => 10428108
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-01
[patent_title] => Difluoroketamide derivatives
[patent_app_type] => utility
[patent_app_number] => 15/805521
[patent_app_country] => US
[patent_app_date] => 2017-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12891
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 273
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15805521
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/805521 | Difluoroketamide derivatives | Nov 6, 2017 | Issued |
Array
(
[id] => 12702067
[patent_doc_number] => 20180125855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-10
[patent_title] => SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 15/806165
[patent_app_country] => US
[patent_app_date] => 2017-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46207
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15806165
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/806165 | Substituted quinazolines for inhibiting kinase activity | Nov 6, 2017 | Issued |
Array
(
[id] => 15407885
[patent_doc_number] => 20200024264
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/348797
[patent_app_country] => US
[patent_app_date] => 2017-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 135232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348797
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/348797 | Anthelmintic quinoline-3-carboxamide derivatives | Nov 5, 2017 | Issued |
Array
(
[id] => 16842820
[patent_doc_number] => 11014892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-25
[patent_title] => 5HT1F receptor agonists and mitochondrial biogenesis
[patent_app_type] => utility
[patent_app_number] => 16/347163
[patent_app_country] => US
[patent_app_date] => 2017-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 9782
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347163
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/347163 | 5HT1F receptor agonists and mitochondrial biogenesis | Nov 1, 2017 | Issued |
Array
(
[id] => 17571063
[patent_doc_number] => 11319321
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-03
[patent_title] => [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/346745
[patent_app_country] => US
[patent_app_date] => 2017-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16562
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 200
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346745
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/346745 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | Oct 30, 2017 | Issued |
Array
(
[id] => 12680650
[patent_doc_number] => 20180118716
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-03
[patent_title] => Chemical Process
[patent_app_type] => utility
[patent_app_number] => 15/796615
[patent_app_country] => US
[patent_app_date] => 2017-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796615
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/796615 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | Oct 26, 2017 | Issued |
Array
(
[id] => 15023283
[patent_doc_number] => 20190322646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => CRYSTALLINE FORMS OF AP26113, AND PREPARATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/344443
[patent_app_country] => US
[patent_app_date] => 2017-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5604
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344443
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/344443 | Crystalline forms of AP26113, and preparation method thereof | Oct 24, 2017 | Issued |
Array
(
[id] => 16786021
[patent_doc_number] => 10988433
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-27
[patent_title] => Cyclohexyl GPR40 agonists for the treatment of type II diabetes
[patent_app_type] => utility
[patent_app_number] => 16/342697
[patent_app_country] => US
[patent_app_date] => 2017-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44138
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342697
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/342697 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | Oct 23, 2017 | Issued |
Array
(
[id] => 12183998
[patent_doc_number] => 20180042935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-15
[patent_title] => 'THERAMUTEIN MODULATORS'
[patent_app_type] => utility
[patent_app_number] => 15/789476
[patent_app_country] => US
[patent_app_date] => 2017-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 27386
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789476
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/789476 | Theramutein modulators | Oct 19, 2017 | Issued |